title: Screening for pancreatic cancer: current evidence and future directions.
abstract: Despite improvements in the clinical and surgical management of pancreatic cancer, limited strides have been made in the early detection of this highly lethal malignancy. The majority of localized pancreatic tumors are asymptomatic, and the recognized presenting symptoms of pancreatic adenocarcinoma are often vague and heterogeneous in nature. These factors, coupled with the lack of a sensitive and noninvasive screening method, have made population-based screening for pancreatic cancer impossible. Nevertheless, at least two large institutions have performed multimodality-screening protocols for individuals with high risk of pancreatic cancer based on genetic predisposition and strong family history. Abnormalities noted during these screening protocols prompted further investigation or surgery that resulted in the discovery of benign, potentially malignant, and malignant pancreatic lesions. In addition to ductal epithelial pancreatic intraepithelial neoplasia, greater sensitivity has recently been achieved in the identification and characterization of precancerous mucinous pancreatic tumors. Advancements in proteomics and DNA microarray technology may confirm serum-based biomarkers that could be incorporated into future screening algorithms for pancreatic cancer.
authors.affiliation: Dr. Greer serves as Research Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh Medical Center where Dr. Brand is Visiting Professor of Medicine. Dr. Brand serves as Academic Director of Shadyside Hospital and Director of the GI Malignancy Early Detection, Screening, and Prevention Program at the University of Pittsburgh and the University of Pittsburgh Medical Center.
authors.forename: Julia B
authors.initials: JB
authors.lastname: Greer
authors.forename: Randall E
authors.initials: RE
authors.lastname: Brand